This post was originally published on this sitehttps://i-invdn-com.akamaized.net/trkd-images/LYNXMPEF8Q14C_L.jpg
(Reuters) – The U.S. Securities and Exchange Commission on Friday sued Mylan NV (O:), accusing it of failing to timely disclose a possible loss related to a Department of Justice probe into whether the company overcharged Medicaid by hundreds of millions of dollars for sales of the EpiPen Auto-Injector.
In a complaint filed with the federal court in Washington, D.C., the SEC accused Mylan of misclassifying EpiPen, which is used to treat severe allergic reactions, as a “generic” or “non-innovator” drug.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.